Trials / Withdrawn
WithdrawnNCT01355783
A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate whether treatment of E7777 in combination with CHOP has superior efficacy compared with CHOP alone in improving complete response rate (CRR) in first line treatment of subjects with Peripheral T-cell Lymphoma (PTCL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E7777 | Treatment in both arms is for 6 cycles at 21 days/cycle. |
Timeline
- Start date
- 2011-03-01
- Primary completion
- 2014-10-01
- Completion
- 2014-11-01
- First posted
- 2011-05-18
- Last updated
- 2013-11-18
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01355783. Inclusion in this directory is not an endorsement.